General Information

Inversago Pharma Inc.

	Address	1155 René-Lévesque Blvd. West Suite 4100 Montréal, H3B 3V2 Canada
	Address type	Registered Office Address
	Address province	Quebec

	Corporation ID	9300813
	Business number	821124369
	Status	Active
	ACT	Canada Business Corporations Act
	Anniversary date	05/20/2015
	Last annual filing	2026
	Data verified	10/31/2026

Description

Inversago Pharma Inc. is an active company registered under Canada Business Corporations Act with a corporation no 9300813 (business no 821124369). The incorporation was done on 2015-05-20. The company is based in Montréal at 1155 René-Lévesque Blvd. West, Suite 4100, H3B 3V2 in Quebec province. As far as we managed to find out, the last annual meeting was on 2017-05-23.
Other corporations in the vicinity are: Autoparc Stanley Inc., Seawill Asset Holdings Ltd., Calamp Northstar Holdings Inc., 8769249 Canada Inc., 173945 Canada Inc..

Location: Statistics Canada, Open Database of Addresses (Open Government Licence – Canada).

Company names

Name	Effective date	Type	Current
INVERSAGO PHARMA INC.	05/20/2015	Corporate Name	true

Directors

Jamie Stiff
,

Carlo Incerti
,

Tara Nickerson
,

Marco Boorsma
,

Dennis D. Kim
,

François Ravenelle
,

last updated: 2026-10-30

Government Grants and Contributions

3 federal grants and contributions between 2019 and 2022 with a total value of $579,500.

Start date	Department and program	Value
05/02/2022	National Research Council Canada Industrial Research Assistance Program – Youth Employment Program (contribution) YOUTH Project: Manufacturing and Regulatory Affairs This project will serve to advance Inversago’s CB1 inverse agonist development programs to provide new therapies aimed at improving the lives of patients affected by metabolic and fibrotic conditions.	$30,000
09/13/2021	National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) Development of Novel CB1 Blockers The ultimate goal of the project is to develop new generation CB1 receptor blockers for clinical advancement applying key learnings from its CB1 receptor antagonist program.	$249,500
07/15/2019	National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) Prader-Willi syndrome - therapy development. Chemical manufacturing process scale-up and optimization of API as well as formulation development and in vivo confirmation.	$300,000

Source: Government of Canada, proactive disclosure of grants and contributions. Contains information licensed under the Open Government Licence – Canada.

Company activities

Date	Type	Section
05/20/2015	Incorporation
02/20/2020	Amendment	6
07/04/2018	Amendment	6

Company annual return

Meeting date	Type of corporation	Year of filing
05/23/2017	Non-distributing corporation with 50 or fewer shareholders	2017
05/20/2016	Non-distributing corporation with 50 or fewer shareholders	2016

Companies nearby